These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

820 related items for PubMed ID: 24345920

  • 1. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
    Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W.
    Clin Cancer Res; 2013 Dec 15; 19(24):6696-702. PubMed ID: 24345920
    [Abstract] [Full Text] [Related]

  • 2. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS, Jung M, Kang HN, Kim H, Park CW, Kim SM, Shin SJ, Kim SH, Kim SG, Kim EK, Yun MR, Zheng Z, Chung KY, Greenbowe J, Ali SM, Kim TM, Cho BC.
    Oncogene; 2017 Jun 08; 36(23):3334-3345. PubMed ID: 28092667
    [Abstract] [Full Text] [Related]

  • 3. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
    Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A.
    Clin Cancer Res; 2020 Jul 15; 26(14):3803-3818. PubMed ID: 32234759
    [Abstract] [Full Text] [Related]

  • 4. Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.
    Bezić J, Tomić I, Pavić M.
    Acta Dermatovenerol Croat; 2024 Mar 15; 32(1):75-76. PubMed ID: 38946192
    [Abstract] [Full Text] [Related]

  • 5. Testing for BRAF fusions in patients with advanced BRAF/NRAS/KIT wild-type melanomas permits to identify patients who could benefit of anti-MEK targeted therapy.
    Le Flahec G, Briolais M, Guibourg B, Lemasson G, Grippari JL, Ledé F, Marcorelles P, Uguen A.
    J Clin Pathol; 2020 Feb 15; 73(2):116-119. PubMed ID: 31506288
    [Abstract] [Full Text] [Related]

  • 6. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
    Hutchinson KE, Johnson DB, Johnson AS, Sanchez V, Kuba M, Lu P, Chen X, Kelley MC, Wang Q, Zhao Z, Kris M, Berger MF, Sosman JA, Pao W.
    Oncotarget; 2015 Sep 08; 6(26):22348-60. PubMed ID: 26084293
    [Abstract] [Full Text] [Related]

  • 7. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
    Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W.
    Cancer Discov; 2012 Sep 08; 2(9):791-7. PubMed ID: 22798288
    [Abstract] [Full Text] [Related]

  • 8. Clinical Development of BRAF plus MEK Inhibitor Combinations.
    Subbiah V, Baik C, Kirkwood JM.
    Trends Cancer; 2020 Sep 08; 6(9):797-810. PubMed ID: 32540454
    [Abstract] [Full Text] [Related]

  • 9. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L, Mazzotta A, Garofoli M, Di Fonte R, Guida G, Guida M, Tommasi S, Azzariti A.
    Biomed Pharmacother; 2021 Jan 08; 133():111006. PubMed ID: 33202284
    [Abstract] [Full Text] [Related]

  • 10. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA.
    Cancer Discov; 2014 Jan 08; 4(1):61-8. PubMed ID: 24265154
    [Abstract] [Full Text] [Related]

  • 11. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V.
    Magy Onkol; 2013 Jun 08; 57(2):96-9. PubMed ID: 23795354
    [Abstract] [Full Text] [Related]

  • 12. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
    Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM.
    Clin Cancer Res; 2016 Dec 15; 22(24):6088-6098. PubMed ID: 27515299
    [Abstract] [Full Text] [Related]

  • 13. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.
    Cancer Res; 2013 Dec 01; 73(23):7043-55. PubMed ID: 24121489
    [Abstract] [Full Text] [Related]

  • 14. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
    Faghfuri E, Nikfar S, Niaz K, Faramarzi MA, Abdollahi M.
    Expert Opin Drug Metab Toxicol; 2018 Mar 01; 14(3):317-330. PubMed ID: 29363351
    [Abstract] [Full Text] [Related]

  • 15. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA.
    JAMA Oncol; 2016 Aug 01; 2(8):1056-64. PubMed ID: 27124486
    [Abstract] [Full Text] [Related]

  • 16. BRAF fusions identified in melanomas have variable treatment responses and phenotypes.
    Turner JA, Bemis JGT, Bagby SM, Capasso A, Yacob BW, Chimed TS, Van Gulick R, Lee H, Tobin R, Tentler JJ, Pitts T, McCarter M, Robinson WA, Couts KL.
    Oncogene; 2019 Feb 01; 38(8):1296-1308. PubMed ID: 30254212
    [Abstract] [Full Text] [Related]

  • 17. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.
    Matrix Biol; 2015 Oct 01; 48():66-77. PubMed ID: 25989506
    [Abstract] [Full Text] [Related]

  • 18. Targeted therapies for cutaneous melanoma.
    Kee D, McArthur G.
    Hematol Oncol Clin North Am; 2014 Jun 01; 28(3):491-505. PubMed ID: 24880943
    [Abstract] [Full Text] [Related]

  • 19. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
    Lokhandwala PM, Tseng LH, Rodriguez E, Zheng G, Pallavajjalla A, Gocke CD, Eshleman JR, Lin MT.
    BMC Cancer; 2019 Jul 05; 19(1):665. PubMed ID: 31277584
    [Abstract] [Full Text] [Related]

  • 20. The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
    Whipple CA, Boni A, Fisher JL, Hampton TH, Tsongalis GJ, Mellinger DL, Yan S, Tafe LJ, Brinckerhoff CE, Turk MJ, Mullins DW, Fadul CE, Ernstoff MS.
    Melanoma Res; 2016 Jun 05; 26(3):223-35. PubMed ID: 26974965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.